{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:00:37Z","timestamp":1791478837217,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003356"],"award-info":[{"award-number":["82003356"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ-511"],"award-info":[{"award-number":["2019JQ-511"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic-Clinical Fusion Innovation Project of Xi\u2019an Jiaotong University Medicine","award":["YXJLRH2022095"],"award-info":[{"award-number":["YXJLRH2022095"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01896-1","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:01:12Z","timestamp":1744192872000},"page":"1215-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1007","volume":"47","author":[{"given":"Kaidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1286-903X","authenticated-orcid":false,"given":"Chen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"19","key":"1896_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"14","key":"1896_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3238\/arztebl.m2024.0064","volume":"121","author":"U Mrowietz","year":"2024","unstructured":"Mrowietz U, Lauffer F, Sondermann W, et al. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024;121(14):467\u201372. https:\/\/doi.org\/10.3238\/arztebl.m2024.0064.","journal-title":"Dtsch Arztebl Int"},{"issue":"10281","key":"1896_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/s0140-6736(20)32549-6.","journal-title":"Lancet"},{"key":"1896_CR4","doi-asserted-by":"publisher","unstructured":"Sommer R, Mrowietz U, Gaarn Du Jardin K, et al. Implementing well-being in the management of psoriasis: an expert recommendation. J Eur Acad Dermatol Venereol. 2024;38(2):302\u201310; https:\/\/doi.org\/10.1111\/jdv.19567.","DOI":"10.1111\/jdv.19567"},{"key":"1896_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106642","volume":"189","author":"R Roskoski Jr","year":"2023","unstructured":"Roskoski R Jr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642. https:\/\/doi.org\/10.1016\/j.phrs.2022.106642.","journal-title":"Pharmacol Res"},{"key":"1896_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925","author":"B Strober","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al. Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.19925.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1896_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"5","key":"1896_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454\u201363. https:\/\/doi.org\/10.1056\/NEJMra1510059.","journal-title":"N Engl J Med"},{"issue":"2","key":"1896_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, et al. Emerging causes of drug-Induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819\u201329.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1896_CR10","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","volume":"15","author":"K Zhao","year":"2024","unstructured":"Zhao K, Zhao Y, Xiao S, et al. Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data. Front Pharmacol. 2024;189:106642. https:\/\/doi.org\/10.3389\/fphar.2024.1458438.","journal-title":"Front Pharmacol"},{"key":"1896_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01869-4","author":"Q Gong","year":"2025","unstructured":"Gong Q, Zhang L, Wu H, et al. Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01869-4.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"1896_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11096-024-01804-z","volume":"47","author":"C Deng","year":"2025","unstructured":"Deng C, Lin X, Ni D, et al. Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA adverse event reporting system. Int J Clin Pharm. 2025;47(1):46\u201352. https:\/\/doi.org\/10.1007\/s11096-024-01804-z.","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"1896_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(12):1339\u201345. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3830.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1896_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2019380.","journal-title":"N Engl J Med"},{"issue":"2","key":"1896_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind. Placebo-controlled trial arthritis rheumatol. 2023;75(2):242\u201352. https:\/\/doi.org\/10.1002\/art.42391.","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"issue":"1","key":"1896_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1896_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1896_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/ced.13919","volume":"44","author":"V Singam","year":"2019","unstructured":"Singam V, Rastogi S, Patel KR, et al. The mental health burden in acne vulgaris and rosacea: an analysis of the US national inpatient sample. Clin Exp Dermatol. 2019;44(7):766\u201372. https:\/\/doi.org\/10.1111\/ced.13919.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"1896_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jamadermatol.2021.2185","volume":"157","author":"JS Barbieri","year":"2021","unstructured":"Barbieri JS, Fulton R, Neergaard R, et al. Patient perspectives on the lived experience of acne and Its treatment among adult women with acne: a qualitative study. JAMA Dermatol. 2021;157(9):1040\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2185.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"1896_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjd.13749","volume":"172","author":"O Revol","year":"2015","unstructured":"Revol O, Milliez N, Gerard D. Psychological impact of acne on 21st-century adolescents: decoding for better care. Br J Dermatol. 2015;172(Suppl 1):52\u20138. https:\/\/doi.org\/10.1111\/bjd.13749.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1896_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cger.2023.09.003","volume":"40","author":"S Mehrmal","year":"2024","unstructured":"Mehrmal S, Mojica R, Guo AM, et al. Diagnostic methods and management strategies of herpes simplex and herpes zoster infections. Clin Geriatr Med. 2024;40(1):147\u201375. https:\/\/doi.org\/10.1016\/j.cger.2023.09.003.","journal-title":"Clin Geriatr Med"},{"key":"1896_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104840","volume":"97","author":"LT Jensen","year":"2023","unstructured":"Jensen LT, Attfield KE, Feldmann M, et al. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine. 2023;189:106642. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104840.","journal-title":"EBioMedicine"},{"issue":"1","key":"1896_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","volume":"86","author":"JG Krueger","year":"2022","unstructured":"Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148\u201357. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.869.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1896_CR24","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s13555-023-01050-7","volume":"13","author":"S Jing","year":"2023","unstructured":"Jing S, Lin Y, Dockens R, et al. Pharmacokinetics and safety of the tyrosine kinase 2 inhibitor deucravacitinib in healthy Chinese subjects. Dermatol Ther (Heidelb). 2023;13(12):3153\u201364. https:\/\/doi.org\/10.1007\/s13555-023-01050-7.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1896_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221664.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1896_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, et al. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729\u201349. https:\/\/doi.org\/10.1007\/s13555-023-00892-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1896_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/13543784.2024.2337736","volume":"33","author":"EF Morand","year":"2024","unstructured":"Morand EF, Pike M, Merrill J, et al. Plain language summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus. Expert Opin Investig Drugs. 2024;33(5):431\u201340. https:\/\/doi.org\/10.1080\/13543784.2024.2337736.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01896-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:30:38Z","timestamp":1757665838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01896-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01896-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}